Skip to Content

Kineret (anakinra) Disease Interactions

There are 5 disease interactions with Kineret (anakinra):


Anakinra (applies to Kineret) infections

Major Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Anakinra has been associated with an increased incidence of serious infections. Therapy should be discontinued if a patient develops a serious infection. The risks should be weighed against the benefits for continued treatment. Therapy should not be started in patients with active infections.


Anakinra (applies to Kineret) renal deficiency

Major Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Anakinra is substantially excreted by the kidney. The risk of toxic reactions to this drug may be greater in patients with impaired renal function. It is recommended to consider administration of the prescribed dose to every other day for patients who have severe renal impairment or those with end-stage renal disease. Monitoring of renal function is recommended.


TNF blocking agents (applies to Kineret) tuberculosis

Major Potential Hazard, Moderate plausibility. Applicable conditions: Tuberculosis -- Active, Tuberculosis -- Latent

Cases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients receiving TNF blocking agents, including patients who have previously received treatment for latent or active tuberculosis. Cases of active tuberculosis have also occurred in patients being treated with these agents during treatment for latent tuberculosis. Prior to initiating TNF blocking agents, patients should be screened for latent tuberculosis infection with a tuberculin skin test and periodically during therapy. Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with TNF blocking agents. Anti-tuberculosis therapy should also be considered prior to initiation of therapy in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection. Tuberculosis should be strongly considered in patients who develop a new infection during treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of tuberculosis, or who have had close contact with a person with active tuberculosis.


Anakinra (applies to Kineret) liver disease

Moderate Potential Hazard, Moderate plausibility.

No formal studies have been conducted examining the pharmacokinetics of anakinra administered in patients with hepatic impairment. Caution is recommended when prescribing for these patients.


Anakinra (applies to Kineret) neutropenia

Moderate Potential Hazard, Moderate plausibility.

The use of anakinra has been associated with neutropenia (ANC < 1 x 10^9/L). Neutrophil counts should be assessed prior to and during treatment. It is recommended to monitor monthly for 3 months, and thereafter quarterly for a period up to 1 year.

Kineret (anakinra) drug interactions

There are 351 drug interactions with Kineret (anakinra)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.